Cryo-Cell International Inc. (CCEL) Releases Earnings Results
Cryo-Cell International Inc. (OTCMKTS:CCEL) released its quarterly earnings data on Friday. The company reported $0.06 EPS for the quarter, Bloomberg Earnings reports. The company had revenue of $6.24 million for the quarter. Cryo-Cell International had a negative return on equity of 26.18% and a negative net margin of 3.07%.
Shares of Cryo-Cell International (CCEL) traded up 7.78% during midday trading on Monday, hitting $6.51. The company had a trading volume of 8,950 shares. Cryo-Cell International has a one year low of $3.38 and a one year high of $6.51. The company’s 50 day moving average is $5.65 and its 200 day moving average is $4.96. The firm’s market cap is $46.24 million.
In related news, CEO Mark L. Portnoy purchased 6,000 shares of Cryo-Cell International stock in a transaction on Friday, May 19th. The stock was bought at an average price of $5.00 per share, with a total value of $30,000.00. Following the completion of the transaction, the chief executive officer now directly owns 521,576 shares of the company’s stock, valued at $2,607,880. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 47.90% of the stock is owned by insiders.
About Cryo-Cell International
Cryo-Cell International, Inc is engaged in cellular processing and cryogenic storage. The Company’s segments include cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacture of Prepacyte CB units, the processing technology used to process umbilical cord blood stem cells.
Receive News & Ratings for Cryo-Cell International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryo-Cell International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.